The Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity

dc.contributor.authorMattila Minttu
dc.contributor.authorSöderström Mirva
dc.contributor.authorAilanen Liisa
dc.contributor.authorSavontaus Eriika
dc.contributor.authorSavontaus Mikko
dc.contributor.organizationfi=kliininen laitos|en=Department of Clinical Medicine|
dc.contributor.organization-code2607100
dc.converis.publication-id44295748
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/44295748
dc.date.accessioned2022-10-28T14:05:48Z
dc.date.available2022-10-28T14:05:48Z
dc.description.abstract<p>Doxorubicin is a potent anticancer drug with cardiotoxicity hampering its use. Neuropeptide Y (NPY) is the most abundant neuropeptide in the heart and a co-transmitter of the sympathetic nervous system that plays a role in cardiac diseases. The aim of this work was to study the impact of NPY on doxorubicin-induced cardiotoxicity. Transgenic mice overexpressing NPY in noradrenergic neurons (NPY-OEDβH) and wild-type mice were treated with a single dose of doxorubicin. Doxorubicin caused cardiotoxicity in both genotypes as demonstrated by decreased weight gain, tendency to reduced ejection fraction, and changes in the expression of several genes relevant to cardiac pathology. Doxorubicin resulted in a tendency to lower ejection fraction in NPY-OEDβH mice more than in wild-type mice. In addition, gain in the whole body lean mass gain was decreased only in NPY-OEDβH mice, suggesting a more severe impact of doxorubicin in this genotype. The effects of doxorubicin on genes expressed in the heart were similar between NPY-OEDβH and wild-type mice. The results demonstrate that doxorubicin at a relatively low dose caused significant cardiotoxicity. There were differences between NPY-OEDβH and wild-type mice in their responses to doxorubicin that suggest NPY to increase susceptibility to cardiotoxicity. This may point to the therapeutic implications as suggested for NPY system in other cardiovascular diseases.<br></p>
dc.format.pagerange338
dc.identifier.eissn1559-0259
dc.identifier.jour-issn1530-7905
dc.identifier.olddbid186233
dc.identifier.oldhandle10024/169327
dc.identifier.urihttps://www.utupub.fi/handle/11111/34658
dc.identifier.urnURN:NBN:fi-fe2021042825069
dc.language.isoen
dc.okm.affiliatedauthorMattila, Minttu
dc.okm.affiliatedauthorSöderström, Mirvamaaria
dc.okm.affiliatedauthorAilanen, Liisa
dc.okm.affiliatedauthorSavontaus, Eriika
dc.okm.affiliatedauthorSavontaus, Mikko
dc.okm.affiliatedauthorDataimport, tyks, vsshp
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA1 ScientificArticle
dc.publisherSpringer
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1007/s12012-019-09557-2
dc.relation.ispartofjournalCardiovascular Toxicology
dc.relation.issue3
dc.relation.volume20
dc.source.identifierhttps://www.utupub.fi/handle/10024/169327
dc.titleThe Effects of Neuropeptide Y Overexpression on the Mouse Model of Doxorubicin-Induced Cardiotoxicity
dc.year.issued2020

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
Mattila2019_Article_TheEffectsOfNeuropeptideYOvere.pdf
Size:
1.13 MB
Format:
Adobe Portable Document Format
Description:
Publishers pdf